Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 Jan 31;: Authors: Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE Abstract Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype. PMID: 29385237 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Pharmacol Ther Source Type: research

Related Links:

This study aimed to characterize women ’ s socioeconomic and epidemiological profile in Uberaba according to the breast cancer screening practice and identify associated factors with this practice. This is a cross-sectional research part of the Women ’ s Health Survey in Uberaba (MG). Data was collected by home interview, referring to socioeconomic and epidemiological issues and breast cancer screening practice, from a sample of 1,520 women above 20 years of age. After processing the data, we performed statistical analysis with measures of association by the Chi-square test, bivariate and multivariate Poisson r...
Source: Ciencia e Saude Coletiva - Category: Occupational Health Source Type: research
Authors: Rampogu S, Parameswaran S, Lemuel MR, Lee KW Abstract Fenugreek (Trigonella foenum-graecum) is used as a spice throughout the world. It is known for its medicinal properties such as antidiabetic, anticarcinogenic, and immunological activities. The present study shows the properties and the nutritional quality of fenugreek seed extract and focuses on screening of active compounds in drug designing for type 2 diabetes and breast cancer. Quantitative analysis was used to calculate the percentages of protein, carbohydrates moisture, fatty acid, galactomannan, oil, and amino acid. Phytochemical analysis reveale...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
This study aimed to investigate the effects of crude graviola extract in vitro on breast cancer cells; in particular, we aimed to identify an agent against triple negative breast cancer (TNBC). We used the TNBC MDA-MB-231 cell line as the experimental model and the ER(+) non-TNBC MCF-7 breast cancer cell line as the control. We identified annonaceous acetogenins, including annonacin isomers, characteristic to this plant by using liquid chromatography tandem mass spectrometry (LC/MS/MS). We observed a significant decrease in the cell viability in both cell lines within 48 h, whereas impaired cell motility and invasiveness w...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Conditions:   Metastatic Ovarian Cancer;   Triple Negative Breast Cancer Intervention:   Biological: Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties. Sponsor:   Immune System Key Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7 Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   HER2+ Breast Cancer Interventions:   Biological: VRP-HER2;   Biological: Pembrolizumab Sponsors:   Herbert Lyerly;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion: Our study revealed that ω-3 PUFA enhanced the anti-tumor activity of Rp while minimizing its side effectsin vitro andin vivo. These results provide novel insights into the mechanisms underlying the potential beneficial effects of Rp combined with ω-3 PUFAs on the prevention of breast cancer.Cell Physiol Biochem 2018;48:2318 –2336
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
This study examines whether cancers that are classified as HER2-amplified with an alternate probe are clinicopathologically similar to those that are classified as such using the HER2/CEP17 probe. Reports for 1201 breast cancers were reviewed, and clinicopathologic findings were compared between HER2/CEP17-equivocal cases that became HER2-amplified using the alternate probe (group A: n=48), HER2-amplified cases using the HER2/CEP17 probe (group B: n=169), and HER2-nonamplified cases using the HER2/CEP17 probe (group C: n=910). Of 1201 cases tested using the HER2/CEP17 probe, 169 (14%) were HER2-amplified, 122 (10%) were eq...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | Study | Tamoxifen